Aveo gets Fotivda over the line in the US, but the market celebration looks misplaced.
Acadia becomes the latest to fall foul of the US FDA's apparently increasingly strict stance.
As with antibodies, the next step will be proving that T cells can grant immunity.
March will see big US decisions for Evrenzo and ide-cel, while tanezumab goes in front of an advisory committee.
Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.